Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Radiotherapy for Adjuvant Treatment of Intermediate Risk HNSCC
NCT03529422Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2019
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Oct 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03529422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529422.